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Plasma levels of the n-3 polyunsaturated fatty acid eicosapentaenoic acid are 
associated with anti-TNF responsiveness in rheumatoid arthritis, and inhibit 
the etanercept driven rise in Th17 cell differentiation in vitro 
 
Louisa Jeffery, Helena L Fisk, Philip C Calder, Andrew Filer, Karim Raza, Christopher 
D Buckley, Iain McInnes, Peter C Taylor and Benjamin A Fisher 
 
ABSTRACT 
Objective 
To determine whether levels of plasma n-3 PUFAs are associated with response to 
anti-TNF agents in RA, and whether this putative effect may have its basis in 
altering anti-TNF driven Th17 cell differentiation  
Methods 
Plasma was collected at baseline and after three months of anti-TNF treatment in 
22 patients with established RA, and fatty acid composition of the 
phosphatidylcholine (PC) component measured. CD4+CD25- T cells and 
monocytes were purified from the blood of healthy donors and co-cultured in the 
presence of anti-CD3, with or without etanercept, EPA or the control fatty acid, 
linoleic acid (LA). Expression of IL-17 and IFNγ was measured by intracellular 
staining and flow cytometry.  
Results 
Plasma PC EPA levels, and the EPA/arachidonic acid ratio, correlated inversely 
with change in DAS28 scores at 3 months (-0.51; p=0.007, and -0.48; p=0.01 
respectively), indicating that higher plasma EPA was associated with a greater 
reduction in DAS28. Plasma PC EPA was positively associated with EULAR 
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response (P=0.02). An increase in Th17 cells post-therapy has been associated 
with non-response to anti-TNF. Etanercept increased Th17 frequencies in vitro. 
Physiological concentrations of EPA, but not LA, prevented this. 
Conclusion 
EPA status was associated with clinical improvements to anti-TNF therapy in vivo 
and prevented the effect of etanercept on Th17 cells in vitro. EPA supplementation 
might be a simple way to improve anti-TNF outcomes in RA patients by 
suppressing Th17 frequencies. 
 
Key Words 
Rheumatoid arthritis, Anti-TNF, polyunsaturated fatty acids, eicosapentaenoic 
acid, omega-3, Th17 
 
L Jeffery PhD, A Filer PhD, K Raza PhD, CD Buckley PhD and BA Fisher MD(Res), 
Rheumatology Research Group and Arthritis Research UK Rheumatoid Arthritis 
Pathogenesis Centre of Excellence (RACE), University of Birmingham, Birmingham, 
UK. 
HL Fisk BSc, PC Calder PhD, Human Development & Health Academic Unit, Faculty of 
Medicine, University of Southampton, Southampton UK and NIHR Southampton 
Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust 
and University of Southampton, Southampton, UK  
I McInnes PhD, Glasgow Biomedical Research Centre, University of Glasgow, Glasgow 
UK 
PC Taylor PhD, Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK.  
 
Correspondence and reprints: 
Dr Benjamin Fisher 
Rheumatology Research Group, Centre for Translational Inflammation Research, 
Queen Elizabeth Hospital Birmingham, Birmingham, B15 2WB, UK 
b.fisher@bham.ac.uk 
EPA and anti-TNF response 3 
 
Introduction 
 
Anti-TNF agents have revolutionised the management of severe rheumatoid 
arthritis (RA), but a substantial proportion of patients either fail to respond or do 
so only partially.1 The reasons for this remain to be fully elucidated but are likely 
to include genetic, genomic and environmental factors.2 In some patients, 
inadequate response may be mediated by an anti-TNF driven rise in pro-
inflammatory Th17 cell differentiation.3 Understanding the reasons for inadequate 
response may guide choice of an alternative biological agent for some patients, or 
optimization of anti-TNF therapy for others, through alteration of environmental 
factors or selection of synergistic agents. 
 
Long-chain n-3 polyunsaturated fatty acids (PUFA), especially eicosapentaenoic 
acid (EPA; 20:5n-3) and docosahexaenoic acid (DHA; 22:6n-3), have long-been 
considered to have anti-inflammatory and immunomodulatory actions and a 
number of explanatory mechanisms have been proposed. These include 
modulation of eicosanoid metabolites by competition with arachidonic acid (AA) 
and inhibition of cyclooxygenase, alteration of lipid rafts, signaling through 
receptors such as GPR120 and PPARγ, and generation of pro-resolution 
mediators.4;5 N-3 (also known as omega 3) PUFA derive their name from having 
their first double-bond at the third carbon atom from the methyl end of their fatty 
acyl chain.6 They cannot be synthesized de novo by animals and most human 
dietary intake is in the form of plant-derived α-linolenic acid (18:3n-3).7;8 α-
linolenic acid is metabolised by a series of desaturation and elongation steps to the 
longer chain EPA and DHA. This process of conversion into longer-chain PUFA is 
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poor in humans,9 and is in direct competition with the desaturation and elongation 
of the considerably more abundant n-6 (omega 6) PUFAs. Therefore in humans, 
most EPA and DHA is of dietary origin, with marine foods being especially good 
sources but having a highly variable intake.  
 
Fish oils contain EPA and DHA. Fish oils ameliorate collagen-induced arthritis,10-12 
and demonstrate modest effects on RA with a consistent reduction in tender joint 
count, morning stiffness and non-steroidal anti-inflammatory drug (NSAID) usage 
being observed in multiple small clinical trials when added to conventional 
DMARD therapy.13-25  Studies suggest that higher doses of fish oil (e.g. 3-6 g/day) 
are more effective than lower doses. Beneficial effects continue to be seen when 
fish oil is added to triple DMARD therapy with a treat-to-target approach in early 
RA.26  
 
In this study we sought to determine whether plasma levels of n-3 fatty acids 
correlated with response to anti-TNF in RA, and propose and test a mechanistic 
hypothesis for the heightened responsiveness we observed in association with 
higher EPA levels in the absence of high dose fish oil supplementation. 
 
Materials and Methods 
Patients 
Plasma was available for 22 out of 23 patients with established RA who 
participated in a comparative study of etanercept and infliximab.27 Etanercept is a 
p75 TNF receptor-Fc fusion protein and infliximab is a chimeric monoclonal 
antibody to TNF. Eligible patients were aged ≥18 years, fulfilled 1987 ACR 
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classification criteria for RA, were positive for rheumatoid factor or anti-CCP 
antibodies, had disease duration >6 months and DAS28 >4.0, had previously failed 
at least one DMARD and were on a stable dose of at least 7.5 mg weekly of 
methotrexate. No other DMARDs were allowed within the 4 weeks prior to 
commencing treatment. Participants were randomised to standard dosing of either 
infliximab 3 mg/kg intravenously at weeks 0, 2, 6 and 10, or subcutaneous 
etanercept 25 mg twice weekly. Therapy was kept stable for the first 3 months of 
treatment. The demographics of these patients are presented in Table 1. The study 
was conducted in compliance with the Helsinki declaration and ethical approval 
was obtained from the West Glasgow Ethics Committee (06/S0703/64). All 
subjects gave written informed consent. Clinical trial registration number is 
ISRCTN44880063. 
 
Plasma phosphatidylcholine fatty acids 
Plasma samples from baseline and 3 months were stored at -80°C prior to analysis. 
After addition of dipentadeconoyl phosphatidylcholine as an internal standard, 
total lipids were extracted with chloroform and methanol (2:1 vol/vol) and 
butylated hydroxytoluene added as an antioxidant.  Phosphatidylcholine (the 
major phospholipid in human plasma) was isolated by solid-phase extraction on 
aminopropyl silica cartridges using chloroform to elute triacylglycerol and 
cholesteryl ester fractions prior to elution of phosphatidylcholine with 
chloroform/methanol (60:40 vol:vol). Purified phosphatidylcholine was dissolved 
in toluene and fatty acid methyl esters were produced by reaction with methanol 
containing 2% (vol/vol) sulphuric acid at 50°C for two hours. After cooling and 
neutralization, fatty acid methyl esters were extracted into hexane and separated 
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on a BPX-70 column fitted to a HP6980 gas chromatograph (Hewlett-Packard, Palo 
Alto, US). Helium was used as the running gas and fatty acid methyl esters were 
detected by flame ionization, identified by comparison with previously run 
standards, and quantified using ChemStation software (Agilent Technologies, Palo 
Alto, USA). Data were expressed as absolute concentration (µg/ml plasma), which 
is related to fatty acid consumption.28 Long-chain n-3 PUFA were considered to be 
20:5n-3 (EPA), docosapentaenoic acid (DPA; 22:5n-3) and 22:6n-3 (DHA). 
Activities of desaturase enzymes, and in particular delta-6 desaturase (D6D), are 
considered to be the rate-limiting steps in the conversion of the precursor n-3 
PUFA α-linolenic acid to the longer chain EPA and DHA, as well as in the parallel 
metabolism of n-6 PUFA. Activity of desaturase enzymes can be inferred from 
product to precursor ratios29. Product to precursor ratios were used to estimate 
the activity of the delta-5 (20:4n-6/20:3n-6) and delta-6 18:3n-6/18:2n-6) 
desaturases. 
 
Th17 cell differentiation 
Human CD4+CD25- T cells and autologous monocytes were isolated from 
peripheral blood mononuclear cells obtained from fresh leukocyte reduction 
system cones (National Blood Service, Birmingham UK) by ficoll gradient 
centrifugation. Negative selection reagents (StemCell technologies) were used for 
the enrichment of monocytes and CD4+CD25- T cells and greater than 95% cell 
purity attained as confirmed by flow cytometry using antibodies against CD3, CD4 
and CD14 (BD). CD25 expression on T cells could not be assessed due to 
interference of the anti-CD25-TAC reagent used for the cell selection. Efficient 
depletion of regulatory T cells was therefore determined by staining for FoxP3 and 
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CD127.  
To assess Th17 differentiation, T cells and monocytes were cultured at a ratio of 
one monocyte to five T cells in the presence of anti-CD3 (OKT3 clone) (0.5 μg/ml). 
The cultures were prepared in RPMI 1640 medium supplemented with 50 U/ml 
Penicillin and Streptomycin and 2 mM L-Glutamine (Gibco, Life Technologies) and 
incubated at 37°C, 95% humidity and 5% CO2. After seven days, T cell expression 
of IL-17 and IFNγ was assessed by intracellular cytokine staining and flow 
cytometry. In brief, T cells were re-stimulated for five hours with PMA (50 ng/ml) 
and ionomycin (1 μM). Brefeldin A (10 μg/ml) was added during the final four 
hours to promote cytokine accumulation. Cells were washed with PBS and dead 
cells labeled with a fixable live/dead discrimination dye (Life technologies) before 
fixation for 12 minutes in 3% paraformaldehye. Following one wash with PBS, cells 
were permeabilised with 0.1% saponin-PBS and labeled with antibodies against 
CD3 (BD), IL-17 (ebiosciences) and IFNγ (BD). To assess the effect of etanercept, 
EPA and the control n-6 fatty acid, LA, upon Th17 differentiation, the cultures were 
also supplemented with EPA or LA at 5 ug/ml, with or without etanercept.  
 
Statistical analysis 
Comparison of baseline data between subjects randomized to infliximab versus 
etancercept used the Mann Whitney U test or the independent samples T test 
depending on distribution of data. Subsequent analyses pooled both groups for a 
population size of 22. Comparison of fatty acid levels and product/precursor ratios 
between baseline and week 12 were undertaken using the Wilcoxon Signed Rank 
test. Correlations of plasma fatty acid levels at baseline, week 12 and the mean of 
these time points (mean value considered the primary dependent variable of 
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interest) with change in DAS28 were analysed using Spearman’s rho. The 
relationship of EULAR outcomes to EPA levels, and of EPA tertiles with change in 
DAS28 and its constituents, was tested by one-way ANOVA. Analyses of the clinical 
and in vitro data were undertaken using SPSS 20 and Graphpad Prism 5 
respectively. 
 
Results 
Baseline and 12 weeks 
Baseline demographics are shown in Table 1 and the two treatment groups were 
not statistically different. In order to determine the effect of anti-TNF on 
desaturase activity, we compared fatty acid profiles from baseline and week 12 of 
treatment, with a view to using mean values across time points to give a more 
robust biomarker of PUFA status over the time course of the study. Interestingly 
there was a trend towards a reduction in the 18:3n-6/18:2n-6 ratio following 
treatment with anti-TNF (p=0.05) which might indicate a reduction in D6D activity 
after 12 weeks, being accompanied by a lower mean 18:3n-6 (p=0.08) product, 
0.60 g/ml (IQR 0.52, 1.15) versus 0.51 (IQR 0.47, 0.62), and a higher level of 
22:4n-6 (adrenic acid; p=0.039); 0.15 μg/ml (IQR 0.11, 0.21) versus 0.19 (IQR 0.12, 
0.27). Adrenic acid was the last measurable n-6 PUFA prior to the second delta-6 
desaturase catalysed step. However no significant differences were observed in 
any other fatty acid after anti-TNF treatment, including all the longer chain n-3 
fatty acids (data not shown), and therefore subsequent analyses used the average 
of baseline and week 12 measurements.  
 
Relationship of plasma phosphatidylcholine fatty acids with change in DAS28  
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Table 2 shows the correlations between individual fatty acids, total n-3, n-3/n-6 
and EPA/AA ratios, and desaturase product/precursor ratios with change in 
DAS28 after 3 months of anti-TNF therapy. The most significant correlations with 
time-averaged levels were seen with EPA (-0.51; p=0.007) and the EPA/AA (20:4n-
6) ratio (-0.48; p=0.01) indicating that higher plasma levels of EPA were associated 
with a greater reduction in DAS28 at 3 months after anti-TNF. This association 
with EPA was still statistically significant when restricting the analysis to subjects 
treated with etanercept (r=-0.54; p=0.04), with a trend seen in the infliximab 
group (r=-0.42; p=0.10). 
 
Relationship of plasma phosphatidylcholine EPA levels with EULAR response 
and components of DA28 
At 12 weeks, 6 subjects were EULAR non-responders,30 and 13 and 3 were 
moderate and good responders, respectively. Median EPA levels in these groups 
were 14.8, 19.1 and 29.4 µg/ml respectively (p=0.02; Figure 1). EPA levels were 
next divided into tertiles and the highest tertile was associated with a larger fall in 
DAS28 scores at 12 weeks (p=0.03; Figure 1). Figure 1 also shows the four 
components that comprise the DAS28 score, in relation to tertiles of EPA, with 
trends being observed for ESR (p=0.07) and tender joint count (p=0.15).  
 
Effect of etanercept and EPA on Th17 differentiation 
Poor responses to anti TNF therapy have been associated with increased IL-17 
production and the frequency of Th17 cells.3;31 Therefore, using our established 
monocyte-driven T cell stimulation system to study Th17 differentiation in vitro,32 
we investigated the effect of anti-TNF upon Th17 differentiation. At 
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pharmacologically-relevant concentrations, etanercept promoted a significant, 1.6 
fold increase in the frequency of cells expressing IL-17 (Figure 2A and B). This 
increase in frequency included cells that expressed IL-17 alone, as well as those 
that expressed IL-17 together with IFNγ. By contrast the frequency of cells that 
expressed IFNγ alone was not affected (figure 2B). Treatment with infliximab did 
not significantly increase Th17 frequencies in this assay (data not shown). Given 
that elevated levels of EPA were associated with improved responses to anti-TNF, 
we were interested to see if this could involve downregulation of IL-17 by EPA. 
Thus we repeated monocyte-driven T cell stimulations in the presence of EPA or 
the control n-6 fatty acid, LA.  Neither EPA nor LA affected the frequency of Th17 
cells relative to ethanol carrier control. Importantly, EPA but not LA prevented the 
etanercept induced increase in Th17 frequency (figure 3).  
 
Discussion 
 
In this cohort of RA patients receiving either etanercept or infliximab, higher 
plasma levels of EPA were associated with a greater reduction in DAS28 scores 
following treatment compared to patients with lower plasma EPA. These 
differences were more significant in patients receiving etanercept, and it is 
possible that differences in construct, avidity and immunogenicity may influence 
these findings33. Our observed association may relate to the modest benefits 
previously seen with n-3 PUFA supplementation in RA patients, although a key 
difference is that there was no n-3 PUFA supplementation in our study.13-15 We 
therefore hypothesized that higher levels of EPA may have additional mechanisms 
relevant to anti-TNF treatment. One potentially detrimental effect of anti-TNF 
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therapy is a variable increase in Th17 cells. This is thought to result from the 
reversal of TNF-mediated p40-suppresion, p40 being a subunit of IL-23 which is 
important in Th17 cell differentiation.34 Higher production of IL-17 has been 
associated with non-response to anti-TNF.3;31 and there is currently great interest 
in dual targeting of TNF and IL-17, to optimize biological responses in the face of 
cytokine compensation.35 Were EPA to suppress Th17 differentiation in the 
context of anti-TNF therapy, supplementation with fish oil might present an 
alternative, and potentially safer, combination approach.  
We were able to replicate this anti-TNF-mediated effect on Th17 frequencies in 
vitro, using a co-culture assay of CD4+CD25- T cells stimulated with autologous 
monocytes. Addition of etanercept, a TNF-receptor fusion protein, resulted in 
increased frequencies of IL-17+ cells in a dose-dependent manner. Addition of EPA, 
but not the n-6 LA control, prevented this etanercept-driven increase in Th17 
frequency. 
 
The mechanism behind this observation has not been established, but eicosanoid 
metabolites of the n-6 fatty acid AA have also been associated with promotion of 
Th17 generation. Prostaglandin E2 (PGE2) stimulates IL-23 and IL-1β production 
by macrophages and dendritic cells whilst inhibiting IL-12, and it also increases 
the expression of IL-23 and IL-1β receptors on T cells, so regulating Th17 
differentiation.36 EPA competes with AA for the prostaglandin-generating COX 
enzymes, has an inhibitory effect on this enzyme, and yields the generally less pro-
inflammatory PGE3.37 If alteration of eicosanoid metabolites does influence 
response to anti-TNF therapy, then one might also expect synergism between anti-
TNF drugs and non-steroidal anti-inflammatory drugs (NSAIDs). Notably, some 
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registry studies have indeed found the use of NSAIDs to predict better response to 
anti-TNF,38;39 although this association was not considered at the time to be causal, 
and other studies have not confirmed this.40 Against this eicosanoid hypothesis, 
might be the observation that inhibition of PGE2 production by monocytes ex vivo 
required a relatively high intake of EPA in a dose-response study, although this 
was conducted in healthy volunteers rather than patients with RA41 
Other mechanisms may also be important. In mouse models of colitis, n-3 fatty 
acids have recently been demonstrated to reduce Th17 cell numbers,42;43 thought 
in part to reflect reduced membrane-raft responsiveness to the Th17 polarising 
cytokine IL-6.44 Indeed, it is possible that the ability of Methotrexate to reduce IL-6 
levels may in part explain the benefits of combining this drug with anti-TNF45. 
 
Plasma phosphatidylcholine fatty acids are a better indicator of dietary intake in 
comparison with dietary questionnaires due to the measurement error inherent in 
the latter46, but only reflect dietary intake over the preceding few days or weeks47-
50. We therefore used the average of baseline and week 12 measurements in order 
to obtain a more robust biomarker of PUFA status. It should be noted that an 
individual’s long-chain n-3 PUFA status may be influenced not just by dietary n-3 
intake, but also by the amount of n-6 PUFA in the diet, as these compete for the 
same desaturase and elongase enzymes, and by polymorphisms in the desaturase 
enzymes29. Although our primary analysis focused on time-averaged plasma fatty 
acids, it is of interest that week 12 levels of docosapentaenoic acid (DPA) were also 
negatively correlated with DAS28 levels. The effect of DPA on inflammation is 
relatively under investigated compared with EPA and DHA, but a recent study of 
complete Freund’s adjuvant-induced arthritis in rats found that monoglyceride 
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EPA or DPA, but not DHA, reduced paw swelling, arthritis score and levels of pro-
inflammatory cytokines51. Further investigation of DPA anti-inflammatory effects 
would be warranted. 
 
D6D is considered a rate-limiting step in long-chain PUFA metabolism. The 
transcription and therefore activity of D6D may be upregulated by insulin and 
statins52 and downregulated by long-chain PUFA,53 glucagon, adrenaline, steroids 
and smoking.54;55 Interestingly, there is a recognized association of D6D activity 
and later development of type 2 diabetes, independent of disturbances in glucose 
metabolism.56 The reason for this is not clear, but inflammation is a risk factor for 
insulin resistance57 and our data implies that inflammation may also increase D6D 
activity, providing a possible explanation for this association. Our findings are 
consistent with the observation that TNFα increases hepatic expression of sterol 
regulatory element binding protein-1c (SREBP-1c) in mice,58 since SRBP-1c plays a 
key role in upregulating D6D gene transcription.53 The alteration in D6D activity 
we observed does not explain the association of anti-TNF response with EPA 
levels, as this would predict an opposite relationship, baseline levels of EPA are 
also predictive of response, and D6D activity plays only a small role in the 
conversion of longer chain n-3 fatty acids,9;56 as confirmed by the comparison of 
fatty acid levels pre- and post-anti-TNF. Furthermore baseline levels of EPA were 
also predictive of response. The desaturase activity inferred from these fatty acid 
ratios generally reflects conversion in the liver,4 however monocytes also 
demonstrate D6D and D5D activity,55;59;60 and we cannot rule out the possibility 
that an alteration of desaturase activity may be more pronounced in these cells, 
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which rely on AA, a long-chain n-6 PUFA, for eicosanoid production following 
stimulation. 
 
There are some limitations in this study. The sample size is small and therefore the 
study requires replication. In view of the sample size and the pilot nature of this 
data, we did not apply a Bonferroni correction. We did not measure the fatty acid 
profile in mononuclear cell membranes, which arguably may be more 
physiologically relevant, although these correlate well with plasma levels.61 Finally, 
a causal relationship cannot be assumed from this data. The strengths are a well-
characterised population with a biomarker of fatty acid intake at more than one 
time point. 
 
In summary, we have presented an association of EPA levels with anti-TNF 
response in RA. If replicated in further studies and causality confirmed, dietary 
modulation may provide a simple method for improving outcomes with this 
therapy. 
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Figure 1. Time-averaged plasma EPA levels in patients who were EULAR non-
responders, moderate and good responders at 3 months. Relationship between 
tertiles of time-averaged plasma EPA, and change in Disease Activity Score 28 
(DAS28) and its four constituents [28 swollen and tender joint count (28SJC and 
28TJC), patient visual analogue scale for global disease activity (VAS), and 
erythrocyte sedimentation rate (ESR)], and Health Assessment Questionnaire 
(HAQ) at 3 months is also shown. 
 
Figure 2: Etanercept increases the frequency of IL-17+ T cells. CD4+CD25- T cells 
were stimulated with autologous monocytes for seven days, under increasing 
concentrations of etanercept and the frequency of cells expressing IL-17 and IFNγ 
measured by flow cytometry.    Representative data for control and 2.5μg/ml 
etanercept are shown in A and relative frequencies of IL-17+ and IFNγ+ cells 
across etanercept concentrations 0-10 μg/ml are summarised in B for five donors. 
Significance was tested by ANOVA with Bonferroni post-hoc analysis. Stars and 
crosses indicate significance with respect to minus etanercept. Stars are used for 
IL-17+IFNy- and crosses for IL-17+IFNy+ cells * P<0.05, ** P<0.01, ***P<0.001.  
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Figure 3: Eicosapentaenoic acid inhibits induction of IL-17+ T cells by Etanercept. 
CD4+CD25- T cells were stimulated with autologous monocytes for seven days in 
the presence of ethanol (carrier control), 5 μg/ml Linoleic acid (LA) (control fatty 
acid) or 5 μg/ml Eicosapentaenoic acid (EPA) with or without 2.5 μg/ml 
Etanercept (Et). The frequency of IL-17+ T cells was measured by flow cytometry. 
Bars show the mean frequencies for seven donors. Error bars indicate standard 
deviation. Significance was tested using paired T tests. 
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Figure 2 
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Figure 3 
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Table 1. Patient demographics at study entry. P-values compare the infliximab and 
etanercept arms. RF; rheumatoid factor. CCP; cyclic citrullinated peptides. DAS28; 
Disease Activity Score 28. HAQ; Health Assessment Questionnaire. ESR; 
erythrocyte sedimentation rate. 
 
 Etanercept Infliximab All p value 
N 11 11 22 
Age (y)1 53.5 (15.3) 52.5 (9.6) 53.0 (12.5) 0.85 
Disease 
duration (y)2 
12 (7,15) 10 (2,20) 10 (4, 16.3) 0.22 
Methotrexate 
dose 
(mg/week)1 
14.3 (6.0) 16.6 (4.5) 15.5 (5.3) 0.33 
RF3 9 (82) 8 (73) 17 (77) 1.00 
RF (dilution)2 160 (40,640) 80 (0,640) 120 (30, 640) 0.75 
Anti-CCP3 10 (91) 8 (73) 18 (82) 0.59 
Baseline 
DAS281 
6.38 (0.65) 6.00 (1.45) 6.19 (1.12) 0.44 
Change in 
DAS28 at 12 
weeks1 
-1.80 (1.31) -1.59 (1.12) -1.69 (1.19) 0.69 
HAQ1 1.73 (0.68) 1.61 (0.42) 1.67 (0.56) 0.12 
ESR (mm/hr)2 26 (15, 52) 31 (16, 48) 27.5 (15.8, 
49) 
0.70 
1mean (sd); 2median (IQR); 3number of subjects positive (%) 
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Table 2. Correlations (Spearman’s rho) between plasma phosphatidylcholine n-3 
and n-6 fatty acids (μg/ml) at baseline, week 12 and the averaged concentration 
from both time points, with change in DAS28 score following 12 weeks of anti-TNF 
therapy. Long-chain n-3 PUFA were considered to be 20:5n-3 (EPA), 22:5n-3 and 
22:6n-3 (DHA). Product to precursor ratios were used to estimate the activity of 
the Δ5 (20:4n-6/20:3n-6) and Δ6 (18:3n-6/18:2n-6) desaturases.  
 
Plasma fatty acids 
 
Correlation of plasma fatty acids with change in 
DAS28 (p value) 
Baseline Week 12 Mean 
18:2n-6 0.408* 
(0.03) 
-0.117 
(0.30) 
0.125 
(0.29) 
18:3n-6 0.031 
(0.45) 
0.211 
(0.17) 
0.162 
(0.24) 
18:3n-3 0.138 
(0.27) 
0.216 
(0.17) 
0.162 
(0.24) 
20:2n-6 0.181 
(0.21) 
-0.158 
(0.24) 
0.013 
(0.48) 
20:3n-6 0.072 
(0.38) 
0.034 
(0.44) 
0.067 
(0.38) 
20:4n-6 0.029 
(0.45) 
0.062 
(0.39) 
-0.001 
(0.50) 
20:4n-3 0.072 
(0.38) 
-0.303 
(0.09) 
-0.186 
(0.20) 
20:5n-3 -0.324 
(0.07) 
-0.394* 
(0.04) 
-0.513** 
(0.007) 
22:4n-6 0.132 
(0.28) 
-0.068 
(0.38) 
0.050 
(0.41) 
22:5n-3 0.043 
(0.42) 
-0.368* 
(0.046) 
-0.269 
(0.11) 
22:6n-3 -0.137 
(0.27) 
-0.113 
(0.31) 
-0.167 
(0.23) 
Total n-3 PUFA -0.187 
(0.20) 
-0.360 
(0.05) 
-0.366* 
(0.047) 
Total long-chain n-3 PUFA -0.190 
(0.20) 
-0.373* 
(0.04) 
-0.425* 
(0.02) 
Total n-6 PUFA 0.301 
(0.09) 
-0.066 
(0.39) 
0.144 
(0.26) 
n-3/n-6 PUFA -0.435* 
(0.02) 
-0.178 
(0.21) 
-0.363* 
(0.048) 
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EPA/AA -0.234 
(0.15) 
-0.535** 
(0.005) 
-0.478* 
(0.01) 
Δ5 desaturase activity 0.001 
(0.50) 
0.128 
(0.29) 
0.058 
(0.40) 
Δ6 desaturase activity -0.241 
(0.14) 
0.047 
(0.42) 
-0.125 
(0.29) 
 
 
 
